Stratified Medicine of Eplerenone in Acute MI/injury (StratMed-MINOCA)

PHASE2RecruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Myocardial Infarction, AcuteMyocardial Infarction with Nonobstructive Coronary ArteriesMyocardial Injury
Interventions
DRUG

Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets

Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.

OTHER

Stratification and standard care

Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.

Trial Locations (2)

G75 8RG

RECRUITING

University Hospital Hairmyres, East Kilbride

Unknown

RECRUITING

Golden Jubilee National Hospital, Glasgow

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

British Heart Foundation

OTHER

collaborator

Abbott

INDUSTRY

lead

NHS National Waiting Times Centre Board

OTHER

NCT05198791 - Stratified Medicine of Eplerenone in Acute MI/injury (StratMed-MINOCA) | Biotech Hunter | Biotech Hunter